Join the 'Sustol' group to help and get support from people like you.
Posted 30 Jun 2017 by Drugs.com
FRIDAY, June 30, 2017 – Your friends are excited to ride that monster roller coaster, but just looking at it makes you queasy. Is there anything you can do to quell your motion sickness so you can join in the fun? If you suffer from motion sickness, there are some ways to deal with it, one doctor says, though riding roller coasters isn't likely an activity you'll ever love. Motion sickness can occur in cars, on planes, boats, trains and amusement park rides, and even when sitting too close to a movie theater screen or using a virtual reality device. Motion sickness occurs when the brain gets mixed information. The brain combines input from the eyes with information from the parts of the body touching the ground, and then links that information with the vestibular system in the ears that controls balance. If these things don't match up, motion sickness can occur. "Some people can feel ... Read more
Related support groups: Nausea/Vomiting, Ativan, Lorazepam, Benadryl, Promethazine, Diphenhydramine, Zofran, Phenergan, Meclizine, Reglan, Ondansetron, Marinol, Dramamine, Motion Sickness, Compazine, Metoclopramide, Prochlorperazine, Perphenazine, Benadryl Allergy, Scopolamine
Heron Therapeutics Announces FDA Approval of Sustol (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Posted 10 Aug 2016 by Drugs.com
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 10, 2016-- Heron Therapeutics, Inc. (NASDAQ:HRTX), today announced that the U.S. Food and Drug Administration (FDA) has approved Sustol (granisetron) extended-release injection. Sustol is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Sustol is an extended-release, injectable 5-HT3 receptor antagonist that utilizes Heron’s Biochronomer® polymer-based drug delivery technology to maintain therapeutic levels of granisetron for ≥5 days, covering both the acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV). “Despite advances in the management of CINV, u ... Read more